利用淋巴瘤表观遗传学改进治疗
本文综述了滤泡性淋巴瘤和弥漫大B细胞淋巴瘤中,遗传改变如何劫持B细胞发育的表观遗传和转录程序,改变转录因子和染色质修饰基因功能,使分化偏向肿瘤起源细胞并改变微环境相互作用,从而提出靶向这些程序的表观遗传修饰剂治疗策略。
要点
- B细胞发育的表观遗传程序在淋巴瘤中被遗传改变劫持。
- 遗传改变影响转录因子和染色质修饰基因, skew分化并改变微环境交互。
- 靶向表观遗传程序可能成为FL和DLBCL的合理治疗策略。
核心结论
- 理解遗传改变扰动表观遗传和转录程序的机制,可识别使用表观遗传修饰剂靶向这些程序的机会。
研究设计与样本
- 综述近期以滤泡性淋巴瘤和弥漫大B细胞淋巴瘤为中心的研究,并结合既往知识。
主要发现
- 生发中心反应中B细胞亲和成熟和终末分化受转录因子调控,通过招募共激活或共抑制复合物表观遗传调节基因表达。
- B细胞内在发育程序调节并响应与滤泡辅助T细胞和滤泡树突状细胞的相互作用。
- B细胞淋巴瘤中遗传改变直接或间接改变转录因子和/或染色质修饰基因功能,劫持发育中的表观遗传和转录程序。
临床怎么用
- 这些见解为合理治疗干预提供了潜在途径,即利用表观遗传修饰剂靶向被扰动的表观遗传和转录程序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Affinity maturation and terminal differentiation of B-cells via the germinal center reaction is a complex multi-step process controlled by transcription factors that induce or suppress large dynamic transcriptional programs. This occurs via the recruitment of co-activator or co-repressor complexes that epigenetically regulate gene expression by post-translationally modifying histones and/or remodeling chromatin structure. B-cell-intrinsic developmental programs both regulate and respond to interactions with other cells in the germinal center that provide survival and differentiation signals, such as T follicular helper cells and follicular dendritic cells. Epigenetic and transcriptional programs that naturally occur during B-cell development are hijacked in B-cell lymphoma by genetic alterations that directly or indirectly change the function of transcription factors and/or chromatin modifying genes. These in turn skew differentiation towards the tumor cell-of-origin and alter interactions between lymphoma B-cells and other cells within the microenvironment. Understanding the mechanisms by which genetic alterations perturb epigenetic and transcriptional programs regulating B-cell development and immune interactions may identify opportunities to target these programs using epigenetic modifying agents. Here, we discuss recently published studies centered on follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) within the context of prior knowledge, and highlight how these insights have informed potential avenues for rational therapeutic interventions.
引用
- Yang H, Green MR. Harnessing lymphoma epigenetics to improve therapies. Blood. 2020. PMID: 33206943. doi:10.1182/blood.2020006908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。